Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Participation grants & abstract awards

Participation grants
The call for participation grant applications has closed on March 1, 2021 (23:59 CET). Participation grant application has closed

Participation Grants (previously called Travel Grants) provide complimentary registration for the upcoming EHA Virtual Congress.

Read more

Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?

During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.

Read more

Registration & accommodation

Register here

Individual RegistrationRegistration fee includes:

Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.

Read more

SWG Educational Activities

2023 was a brainstorming year for the SWG.

Read more